News

Each unit consists of one share of the company’s common stock and a warrant to purchase 0.5 shares of the common stock at a price of $1.5875 per

Subject to the completion of the anticipated analysis of the unblinded trial data, the company plans to seek accelerated conditional approval for BiovaxID in the US, Europe and

The trial began in patients with locally advanced or metastatic cancers that are refractory to standard therapy or for whom no standard therapies exist. The primary objectives of

The study met its primary endpoint, demonstrating less venous procedural pain in those treated with Zingo powder intradermal injection system compared to placebo. Patients received zingo or placebo

Triolex acts by modulating the anti-inflammatory pathway NF-kappaB. The trial is a 28-day study designed to evaluate the safety of the drug candidate and determine the optimal dose

Exelixis is continuing to analyze the data to assess whether further evaluation of the compound is warranted. The results of the potent small molecule inhibitor, XL784 meet the

The Lovaxin C vaccine, being developed by biotechnology company Advaxis, is intended to treat cervical cancer and head and neck cancers that result from the human papilloma virus.

The multinational trial, which will evaluate once daily oral forodesine HCL treatment, will be conducted in accordance with a special protocol assessment agreement between the FDA and BioCryst

The purpose of the trial is to examine the effectiveness of Zyflo at reducing the length of a hospital stay for adults who are hospitalized for a chronic